Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Catalyst Pharm Inc (NQ: CPRX )

21.63 -0.33 (-1.50%)
Streaming Delayed Price Updated: 3:25 PM EST, Dec 5, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 438,197
Open 21.74
Bid (Size) 21.62 (6)
Ask (Size) 21.64 (2)
Prev. Close 21.96
Today's Range 21.50 - 21.92
52wk Range 13.00 - 24.27
Shares Outstanding 102,780,151
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Despite its impressive fundamentals, NASDAQ:CPRX remains undervalued.
CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX), an undervalued stock with good fundamentals. 
Via Chartmill
Why NASDAQ:CPRX qualifies as a high growth stock.
Should you consider CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX) for high growth investing? 
Via Chartmill

Performance

YTD
+26.42%
+26.42%
1 Month
-0.55%
-0.55%
3 Month
+8.64%
+8.64%
6 Month
+32.62%
+32.62%
1 Year
+51.79%
+51.79%

More News

Read More
Is NASDAQ:CPRX on the Verge of a Major Breakout as a Strong Growth Stock?
Via Chartmill
Catalyst Pharmaceuticals Recognized as One of North America’s Fastest-Growing Companies on the 2024 Deloitte Technology Fast 500™ List
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
NASDAQ:CPRX is showing good growth, while it is not too expensive.
Via Chartmill
NASDAQ:CPRX is an undervalued gem with solid fundamentals.
Via Chartmill
Why the growth investor may take a look at CATALYST PHARMACEUTICALS INC (NASDAQ:CPRX).
Via Chartmill
A Peek at Catalyst Pharmaceuticals's Future Earnings
Via Benzinga
Catalyst Pharmaceuticals to Participate in Upcoming Investor Conferences
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
BioNTech Stock Got A IBD RS Rating Lift
Via Investor's Business Daily
Catalyst Pharmaceuticals Recognized Among BioSpace 2025 Best Places to Work
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Vericel Stock Sees RS Rating Shoot Higher
Via Investor's Business Daily
NASDAQ:CPRX, a growth stock which is not overvalued.
Via Chartmill
Smaller Cap Biotechs Are In Season: How Are We Doing?
Via Talk Markets
Catalyst Pharmaceuticals Reports Strong Third Quarter 2024 Financial Results and Provides Corporate Update
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Why NASDAQ:CPRX Is a Promising High-Growth Stock in the Midst of Consolidation.
Via Chartmill
Biotech Momentum Trades For The Q4 Rally
Via Talk Markets
Catalyst Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 6, 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Amphastar Casts Wide Net, Hauls In Profits, Gets Rating Upgrade
Via Investor's Business Daily
NASDAQ:CPRX—Positioned as a High-Growth Stock, Ready for a Potential Breakout.
Via Chartmill
Alkermes Stock Jumps Nearly 30% In 3 Months Amid Hefty Profits
Via Investor's Business Daily
Looking for growth without the hefty price tag? Consider NASDAQ:CPRX.
Via Chartmill
Catalyst Pharmaceuticals Donates $100,000 to the American Red Cross Hurricane Helene Relief Efforts
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals to Participate in the BofA Securities CNS Therapeutics Virtual Conference 2024
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Catalyst Pharmaceuticals Announces Sub-Licensee DyDo Pharma Received Approval to Commercialize FIRDAPSE® in Japan
From Catalyst Pharmaceuticals, Inc.
Via GlobeNewswire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.